Innovative Clinical Trials Aparito specializes in digitizing clinical trials with its Atom5™ eCOA platform, utilizing video assessments, wearables, and ePROs to generate real-world data. This focus presents opportunities to collaborate with pharmaceutical companies and research organizations seeking advanced digital solutions for patient-centric trials.
Recognition and Awards The company's recognition as a finalist in the Innovation in STEM category and receiving the EURORDIS Company Award for Health Technology indicates a strong reputation in health tech innovation, making it an attractive partner for funding, collaborations, and expanding market reach.
Strategic Partnerships Aparito’s collaborations with the University of Birmingham, ISOQOL Australia and New Zealand, and Raazi demonstrate its ability to form partnerships across academic, healthcare, and non-profit sectors, opening sales channels for integrating its solutions into diverse research and healthcare settings.
Growth & Funding With a revenue range of $1M to $10M and recent funding of $1.3M, Aparito is positioned as a growing med-tech company with potential for scale-up. Engaging with organizations looking to invest or deploy cutting-edge digital health platforms could drive further revenue opportunities.
Global Impact Focus The company’s efforts in low-income regions like South Africa and its international partnerships highlight a commitment to global healthcare solutions. This opens opportunities to tailor and offer digital health products to organizations aiming to expand access and improve outcomes in underserved markets.
Aparito - a wholly owned subsidiary of Eli Lilly and Company uses 8 technology products and services including Open Graph, Neo4j, oEmbed, and more. Explore Aparito - a wholly owned subsidiary of Eli Lilly and Company's tech stack below.
| Aparito - a wholly owned subsidiary of Eli Lilly and Company Email Formats | Percentage |
| First.Last@aparito.com | 40% |
| First@aparito.com | 10% |
| First.Last@aparito.com | 40% |
| First@aparito.com | 10% |
Hospitals and Health CareWales, United Kingdom11-50 Employees
Aparito’s mission is to digitise clinical trials and accelerate drug development for patients with life-limiting diseases by supporting patient-centric clinical trials. We do this through our Atom5™ eCOA platform using video assessments, wearable devices and ePROs to generate continuous real-world data.
Company Overview
Media & News
Funding & FinancialsAparito - a wholly owned subsidiary of Eli Lilly and Company has raised a total of $1.3M of funding over 4 rounds. Their latest funding round was raised on Mar 01, 2019 in the amount of $1.3M.
Aparito - a wholly owned subsidiary of Eli Lilly and Company's revenue is estimated to be in the range of $1M$10M
Funding & FinancialsAparito - a wholly owned subsidiary of Eli Lilly and Company has raised a total of $1.3M of funding over 4 rounds. Their latest funding round was raised on Mar 01, 2019 in the amount of $1.3M.
Aparito - a wholly owned subsidiary of Eli Lilly and Company's revenue is estimated to be in the range of $1M$10M
1-888-653-2347 
support@leadiq.com